Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy
Saved in:
| Published in: | Journal of Health Economics and Outcomes Research |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1868552953461211137 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Journal of Health Economics and Outcomes Research |
| description | |
| discipline_display | Health and Safety |
| discipline_facet | Health and Safety |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:69571 |
| institution | FRELIP |
| journal_source_facet | Journal of Health Economics and Outcomes Research |
| last_indexed | 2026-06-20T21:29:00.958Z |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy Health and Safety General Health and Safety |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Health and Safety General Health and Safety |
| subject_facet | Health and Safety General Health and Safety |
| title | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_alt | Costo estimado del manejo de eventos adversos en pacientes con cáncer de pulmón de células no pequeñas sin tratamiento previo con mutaciones comunes de EGFR tratados con amivantamab más lazertinib y osimertinib más quimioterapia Coût estimé de la gestion des événements indésirables chez les patients naïfs de traitement atteints d'un cancer du poumon non à petites cellules avec mutations courantes de l'EGFR traités par amivantamab plus lazertinib et osimertinib plus chimiothérapie Custo estimado do manejo de eventos adversos em pacientes com câncer de pulmão de células não pequenas virgens de tratamento com mutações comuns do EGFR tratados com amivantamabe mais lazertinibe e osimertinibe mais quimioterapia |
| title_auth | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_es_txt | Costo estimado del manejo de eventos adversos en pacientes con cáncer de pulmón de células no pequeñas sin tratamiento previo con mutaciones comunes de EGFR tratados con amivantamab más lazertinib y osimertinib más quimioterapia |
| title_fr_txt | Coût estimé de la gestion des événements indésirables chez les patients naïfs de traitement atteints d'un cancer du poumon non à petites cellules avec mutations courantes de l'EGFR traités par amivantamab plus lazertinib et osimertinib plus chimiothérapie |
| title_full | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_fullStr | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_full_unstemmed | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_pt_txt | Custo estimado do manejo de eventos adversos em pacientes com câncer de pulmão de células não pequenas virgens de tratamento com mutações comuns do EGFR tratados com amivantamabe mais lazertinibe e osimertinibe mais quimioterapia |
| title_short | Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy |
| title_sort | estimated cost of adverse event management in treatment naïve non-small cell lung cancer patients with common egfr mutations treated with amivantamab plus lazertinib and osimertinib plus chemotherapy |
| topic | Health and Safety General Health and Safety |
| url | https://jheor.org/article/161356-estimated-cost-of-adverse-event-management-in-treatment-naive-non-small-cell-lung-cancer-patients-with-common-egfr-mutations-treated-with-amivantamab |